October 22, 2025

AndzonBio2 emerges from stealth mode and announces initial €3M seed funding to advance breakthrough treatments for neurological disorders

Paris, France, October 23, 2025 – AndzonBio2 emerges from stealth mode and announces a €3M ($3.5M) seed funding from AdBio Partners, a venture capital company builder fund specialized in early-stage investments in life sciences, and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm) dedicated to supporting life-science technology transfer and innovation. This initial funding will be used to build a strong preclinical pipeline in neuroinflammation. AndzonBio2 is committed to delivering novel therapies that modulate neuroinflammatory mechanisms and restore balance to the brain to unlock new possibilities for patients with a central nervous system (CNS) condition through a unique portfolio-building approach, attracting the most promising early-stage projects in the field.

AndzonBio2’s leadership team is made of Loic Lhuillier, PhD (co-founder and acting Chief Executive Officer) and Simon Loiodice, PhD (Chief Operating Officer) who bring a long-standing experience in CNS drug development and entrepreneurship. Alongside them, a select group of world-class advisors from the biotech, pharmaceutical and venture capital industries as well as clinicians will provide key strategic and scientific guidance, to accelerate the development of impactful CNS therapies. AndzonBio2 is the second company emerging from the AndzonBio® initiative, which was launched in June 2024 through the strategic alliance between Inserm Transfert and AdBio Partners.

“I am delighted to welcome Inserm Transfert and AdBio Partners in this seed financing” said Loic Lhuillier. “Following a period of search and evaluation of the best neuroinflammation projects Europe has to offer, this investment will allow us to build the company, as well as integrate the first programs in our pipeline and accelerate identification of new treatments in an area of significant needs, but also great promise.”

About AndzonBio2

AndzonBio2 is a neuroscience company with a creative model structured to efficiently turn breakthrough science into therapeutic solutions that target the underpinning causes of neurological disease. The company has a strategic focus on neuroinflammation which is increasingly recognized as critically involved in multiple brain disorders. The company searches, evaluates and integrates the most promising European projects to build and advance a leading portfolio of balanced risk/reward assets in neurology.

About AdBio partners

AdBio partners is an AMF-regulated (the French financial market authority) VC firm that invests in a range of sectors within life sciences - specifically in therapeutics-oriented projects. AdBio partners’ unique strategy combines early-stage investments in promising companies and strong entrepreneurial support to strengthen the company’s growth. Created in 2016, AdBio partners has made 28 European investments in France, Belgium, Spain and Germany with two company builder funds. AdBio partners has developed strong relationships within the European innovation ecosystem; as a result, it has attracted international VC syndicates to its portfolio companies. The operational team is composed of investment professionals with extensive corporate experience, combined with strong scientific, medical and operational expertise.

About Inserm Transfert

Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), is responsible for the value creation of innovations at Inserm and its academic partners in human health and promotes long-term technology transfers in line with international best practices. Inserm Transfert SA was founded in 2000. It manages, under a Public Service Management Contract (Délégation de Service Public), the entire promotion and transfer of knowledge emerging from the Inserm research laboratories to the industrial world, from invention disclosure to industrial partnerships and start-up incorporation. Inserm Transfert also offers services relating to setting up and managing national, European and international projects, as well as supporting the technology transfer of clinical research and health data/databases. In 2009, Inserm Transfert and Inserm established an investment fund to finance proofs of concept. In 2005, Inserm Transfert Initiative, a dedicated seed money fund for life sciences, was created. Since 2017 a pathway for pre-entrepreneurship supports researchers/inventors who aspire to become involved in entrepreneurship. In 2022, Inserm Transfert decided to become LPs in AFB Fund II to increase the opportunity of investment of seed fund in Inserm Transfert spin-off. Inserm-Transfert is at the origin of the AndzonBio® initiative.

Press and analyst contacts

AdBio Partners

Inserm Transfert

AndzonBio2